Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092347 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
A Phase 1 study of Chronic Kidney Disease (CKD), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT05092347 is a Phase 1 study of Chronic Kidney Disease (CKD) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 56 participants, below the 2,262-participant average among 8 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT05092347, a Phase 1 study of Chronic Kidney Disease (CKD), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA
Conditions Studied
Interventions
- DRUG Vonsetamig
Study Locations (10)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine - Orange
- Connie Frank Transplant Center at UCSF - San Francisco
Connecticut
- Yale University of Medicine - New Haven
District of Columbia
- Medstar Georgetown Transplant Institute - 2-PHC - Washington D.C.
Illinois
- Comprehensive Transplant Center - Chicago
Maryland
- John Hopkins Hospital - Baltimore
Minnesota
- University of Minnesota - Minneapolis
New York
- New York University Langone Health - New York
Pennsylvania
- Penn Transplant Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092347
The ClinicalTrials.gov registry entry for NCT05092347 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,262-participant average among 8 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (98% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease (CKD) appearing as the primary indexed condition, and to 1 intervention - of which Vonsetamig is the first listed.
NCT05092347 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Connecticut, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05092347 about?
NCT05092347 is a clinical study titled "A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)". The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other...
What is the current status of trial NCT05092347?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-08-02. Estimated completion is 2027-09-01.
What conditions does trial NCT05092347 study?
This clinical trial studies the following conditions: Chronic Kidney Disease (CKD).
What interventions are being tested in trial NCT05092347?
The interventions under investigation include: Vonsetamig (DRUG).
Who is sponsoring clinical trial NCT05092347?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05092347 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease (CKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
RECRUITING
-
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
RECRUITING · NA
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
RECRUITING
-
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
COMPLETED · Phase 3
-
Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.